Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Zai Lab Limited | Bemarituzumab (FPA144) + chemo - (FORTITUDE-101) | Gastric and gastro-esophageal junction cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Zai Lab Limited | QINLOCK (ripretinib) - (INTRIGUE) | Gastrointestinal Stromal Tumors (GIST) - second-line | Phase 3 | Data Released | Oral | Oncology |
| Zai Lab Limited | Efgartigimod - (ADDRESS) | Pemphigus Vulgaris (PV), Pemphigus Foliaceus (PF) | Phase 3 | Ongoing | Intravenous | Immunology |
| Zai Lab Limited | ZEJULA (Niraparib) - (PRIME) | Ovarian cancer | Phase 3 | Oral | Oncology | |
| Zai Lab Limited | Xanomeline-Trospium (KarXT) (ZL-2701-001) - (China Bridging Trial) | Schizophrenia | Phase 3 | Data Released | Oral | Psychiatric |
| Zai Lab Limited | ZL-1310 (DLL3 ADC) | Solid tumors, relapsed and refractory second-line+ SCLC | Phase 3 | Ongoing | Intravenous | Oncology |
| Zai Lab Limited | ZEJULA (niraparib) - (NORA) | Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) | Phase 3 | Data Released | Oral | Oncology |
| Zai Lab Limited | Efgartigimod | Primary Membranous Nephropathy (pMN) | Phase 2/3 | Trial Planned | Intravenous | Immunology |
